Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
IPO Year:
Exchange: NASDAQ
Website: nutriband.com
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
5/A - NutriBand Inc. (0001676047) (Issuer)
5/A - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo
Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto
Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u
ORLANDO, FL / ACCESSWIRE / December 14, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) on The RedChip Money Report® on Bloomberg TV this Saturday, December 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's Chief Scientific Officer Dr. Jeff Patrick discusses the Company's first-in-class transdermal technology, new CDC guidelines, the technology's application potential, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip
ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, September 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's Chairman & President Serguei Melnik discusses the Company's expanded patents, near-term commercialization plans, Q2 revenue results, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by
ORLANDO, FL / ACCESSWIRE / August 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a 7:6 forward split of its common stock with a record date of Monday, August 15, 2022 (the "Stock Split"). Each shareholder of record as of the record date will receive one (1) additional share of common stock for each six (6) shares held as of the record date.. No fractional shares of common stock will be issued in connection with the Stock Split. Instead, all fractional shares will be rounded up to the next whole share. The payment date for the Stock Split will be August 25, 2022, and the Comp
ORLANDO, FL / ACCESSWIRE / July 21, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, July 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's CEO Gareth Sheridan discusses the Company's strong revenue growth and partnerships, the Company's solution to the growing opioid crisis, the broad IP portfolio, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Repo
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri
SC 13D/A - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13D - NutriBand Inc. (0001676047) (Subject)
8-K - NutriBand Inc. (0001676047) (Filer)
DEF 14A - NutriBand Inc. (0001676047) (Filer)
10-Q - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
10-Q - NutriBand Inc. (0001676047) (Filer)
424B4 - NutriBand Inc. (0001676047) (Filer)
EFFECT - NutriBand Inc. (0001676047) (Filer)
POS AM - NutriBand Inc. (0001676047) (Filer)
POS AM - NutriBand Inc. (0001676047) (Filer)
ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company's achievements in 2024 and the outlook for 2025. Dear Fellow Shareholders, As we close out 2024, I want to extend my deepest gratitude to you, our loyal shareholders, for your continued trust and support. This year has been one of exceptional progress, strategic execution, and transformative milestones for Nutriband. We remain steadfast in our mission to enhance patient safety through innovative transdermal technologies, with a particular focus on combating the opioid crisis and improving
Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025. ORLANDO, Fla., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed the registration requirements to extend its Chinese patent to Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Macao IP Office has assigned number J
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645,796 USD, up 50.94%
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company's AVERSA technology. Information about the Conference can be found here – https://nobleconference.comDetails of Mr. Melniks presentation and live replay will be available on Channelchek and Youtube after the conference. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical
ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Hong Kong Patents Registrar has assigned Publication Number 40085268 B to the patent with a publication date of December 20, 2024. Hong Kong is a Special Administrative Region (SAR) of the Peo
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches. The patent number reflects the issuance of Patent No: ZL 202211158031.The CNIPA issued a prior notice of allowance in September 2024.About AVERSA™ Abuse-Deterrent Transdermal TechnologyNutriband's AVERSA™ ab
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the Company's current operations and upcoming milestones. Nutriband stands at the forefront of addressing the global opioid crisis with its revolutionary AVERSA™ abuse-deterrent transdermal technology. The Company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technologyNutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch productsAVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patchORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patchNutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch productsORLANDO, FL / ACCESSWIRE / September 20, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed a trademark licensing agreement for the use
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding.Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025About Nutriband Inc.We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated i